ArticleInternal medicine (Tokyo, Japan)2026
Significance of 14-3-3 Epsilon for Right Ventricular Failure Associated with Pulmonary Hypertension.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective The pathophysiology of right ventricular failure in patients with pulmonary hypertension has not been completely examined and monitoring strategies are lacking. The 14-3-3 protein family plays a regulatory role in cardiac fibroblasts. This study investigated whether 14-3-3 epsilon, a member of the 14-3-3 protein family, was associated with right ventricular failure. Methods A monocrotaline-induced pulmonary hypertension rat model was used to investigate the role of 14-3-3 epsilon in right ventricular failure. Plasma samples from patients with pulmonary hypertension were analyzed using an enzyme-linked immunosorbent assay for 14-3-3 epsilon. Patients Right ventricular samples from a monocrotaline-induced pulmonary hypertension rat model and plasma samples (n=83) from patients with pulmonary hypertension were used. Results The right ventricular 14-3-3 epsilon expression was higher in the monocrotaline group than in the control group. In patients with pulmonary hypertension, the median plasma 14-3-3 epsilon level was 95 ng/mL. Plasma 14-3-3 epsilon levels were significantly associated with tricuspid lateral annular peak systolic velocity and right ventricular fractional area changes in patients with pulmonary hypertension. Conclusion This is the first study to demonstrate an association between 14-3-3 epsilon and right ventricular failure. Plasma 14-3-3 epsilon level may be a useful circulating marker for evaluating right ventricular dysfunction in patients with pulmonary hypertension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.